Local 12, WCPO highlight brain tumor vaccine trial
Local television stations Local 12 and WCPO recently highlighted the Imvax trial that will test a personalized immunotherapy approach designed to work similarly to a vaccine by training the immune system to fight glioblastomas, a deadly brain tumor.
The University of Cincinnati is a study site for the new Phase 2b clinical trial, and Soma Sengupta, MD, PhD, is the site principal investigator.
In the trial, glioblastoma patients will have their tumors removed, and then their tumor cells will be combined with a novel drug to create a personalized vaccine. The combination is then inserted into the patients' abdomens, allowing the immune system to train to fight the tumor cells.
"The patient is making their own antibodies, and their own immune system is working to try and beat this cancer," Sengupta told Local 12.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
High Court offers protections for therapy speech
April 5, 2026
Jennifer Bard, a professor in the Donald P. Klekamp College of Law and the UC Department of Internal Medicine, spoke with journalists about the US Supreme Court ruling granting first amendment protections for speech offered during therapy sessions.
Scientists discover how snakes stand upright without limbs
April 3, 2026
Smithsonian magazine highlights a study co-authored by UC Professor Bruce Jayne, an expert in snake locomotion, about how snakes stand upright without arms or legs.
On track: Hoffman Honors Scholar studies public transit
April 2, 2026
Public transit is where Zane Sawyer’s lifelong passion for travel meets his commitment to making an impact. The University of Cincinnati first-year geography major in the College of Arts & Sciences and member of the second cohort of Hoffman Honors Scholars (HHS) has hit the ground running, designing a research project intended to capture both how public transit works and how its users perceive it.